KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $563.0 million.

  • Quest Diagnostics' Cash from Operations rose 5814.61% to $563.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 3493.2%. This contributed to the annual value of $1.3 billion for FY2024, which is 487.42% up from last year.
  • Quest Diagnostics' Cash from Operations amounted to $563.0 million in Q3 2025, which was up 5814.61% from $544.0 million recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' Cash from Operations registered a high of $731.0 million during Q1 2021, and its lowest value of $94.0 million during Q1 2023.
  • Its 5-year average for Cash from Operations is $419.9 million, with a median of $460.0 million in 2021.
  • Per our database at Business Quant, Quest Diagnostics' Cash from Operations surged by 19595.14% in 2021 and then crashed by 8041.67% in 2023.
  • Quest Diagnostics' Cash from Operations (Quarter) stood at $481.0 million in 2021, then plummeted by 30.56% to $334.0 million in 2022, then soared by 57.78% to $527.0 million in 2023, then fell by 11.95% to $464.0 million in 2024, then increased by 21.34% to $563.0 million in 2025.
  • Its Cash from Operations stands at $563.0 million for Q3 2025, versus $544.0 million for Q2 2025 and $314.0 million for Q1 2025.